Research
Hormonal
Multi-receptor agonists (e.g., Tirzepatide, Retatrutide) achieve greater weight loss than single-target GLP-1RAs by simultaneously activating multiple gut hormone receptors (GLP-1R, GIPR, GCGR).
Newer 'multi-agonist' drugs like Tirzepatide and Retatrutide are even more effective for weight loss than older GLP-1 drugs, achieving up to 24% body weight loss in trials. They work by targeting multiple hormone receptors. They are taken once weekly. They are prescription medications and can cause gastrointestinal side effects.
StrongSupportsVERY_HIGH confidence
Tirzepatide是一种单分子多肽，可同时激动GIPR和GLP-1RA... Retatrutide是一种GIP/GLP-1/GCG三受体激动剂... 第48周时，12 mg组平均体重减轻可达24.2%
Why this rating
Based on phase 2/3 clinical trials (SURMOUNT-1, Retatrutide phase 2).
Source
The glucagon-like peptide-1 (GLP-1) drugs poised to conquer obesity
Jun Yin et al. · Chinese Science Bulletin (Chinese Version) · 2024
DOI 10.1360/tb-2024-0417
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists (GLP-1RAs) induce significant weight loss in adults with obesity or overweight by acting on the central nervous system to increase satiety and on the gastrointestinal tract to delay gastric emptying.Strong
- GLP-1 receptor agonists provide cardiovascular benefits for patients with obesity, even those without diabetes, by reducing the risk of major adverse cardiovascular events.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →